We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has approved Japanese company Kyowa Kirin’s drug Nourianz (istradefylline) as an add-on to the existing drug levodopa/carbidopa to treat adults...
Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would sell its 50% share in the partnership for $780 million.